Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 1 uM letrozole.Mod Details Premium No Difficulty Mod ID 582 For Link Copy to Clipboard Progesterone receptor positive when grown in medium without letrozole. The MCF-7 cell line was authenticated in January 2014 by DNA profiling using short tandem repeat loci and found to be matching the genetic profile reported for the MCF-7 cell line.īreast cancer cell line resistant to the aromatase inhibitor letrozole. After ~2–3 months, the isolated colonies gave rise to letrozole-resistant cell lines, which could be grown in letrozole-containing medium with a weekly split ratio of ~1:25. Single colonies were transferred to new wells and gradually expanded in medium with letrozole. A culture of MCF-7 cells were treated with 10−6 M letrozole for one week, trypsinized and seeded in serial dilutions in 24-well plates. Letrozole-resistant cell lines were established from MCF-7 cells grown in medium with 10% NCS and 10−7 M testosterone.

Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI letrozole allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment. However, a major problem is development of resistance against AIs. Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients.

The MCF7/Let R-1 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors.

Cyberduck ai